Pancreatic Cancer Research

ResearcherSeoul National UniversityActive in the last 2 years

Hye‐Sol Jung

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2041-4214; OpenAlex author ID A5086366354. Sources: OpenAlex.

Their work

Papers
30 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
44
Papers, trials and grants by year

2022: 1 paper · 2023: 2 papers · 2024: 12 papers · 2025: 10 papers · 2026: 5 papers

Papers 30

  1. Distinct clinicopathologic features and efficacy of adjuvant therapy in intraductal papillary mucinous carcinoma compared with conventional pancreatic ductal a… Co-author DOI 10.1016/j.suronc.2026.102368↗
  2. Efficacy of neoadjuvant FOLFIRINOX in resectable pancreatic cancer (NeoFOL-R): study protocol for an international, multicenter, prospective, randomized contro… Co-author DOI 10.1186/s12885-026-15639-6↗
  3. ASO Visual Abstract: Evaluating Tumor Regression and Survival Outcomes in Pancreatic Ductal Adenocarcinoma After Neoadjuvant Treatment According to CAP Grading… Co-author DOI 10.1245/s10434-025-18349-8↗
  4. Correction: Evaluating Tumor Regression and Survival Outcomes in Pancreatic Ductal Adenocarcinoma After Neoadjuvant Treatment according to CAP Grading System: … Co-author DOI 10.1245/s10434-026-20624-1↗
  5. Comparison of postoperative survival after neoadjuvant treatment versus upfront surgery in resected pancreatic ductal adenocarcinoma: a propensity score matchi… First author DOI 10.4174/astr.2026.111.2.93↗
  6. Metabolic response during preoperative chemotherapy can predict prognosis in pancreatic cancer. Co-author DOI 10.1002/jhbp.12122↗
  7. Long-term oncologic outcomes of robot-assisted pancreaticoduodenectomy versus open pancreaticoduodenectomy for pancreatic cancer. First author DOI 10.1007/s00464-025-11833-y↗
  8. Prognostic implications of resection margin status in distal pancreatectomy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.hpb.2025.04.001↗
  9. The FOXP1-ABCG2 axis promotes the proliferation of cancer stem cells and induces chemoresistance in pancreatic cancer. Co-author DOI 10.1038/s41417-025-00896-7↗
  10. SLC5A3 depletion promotes apoptosis by inducing mitochondrial dysfunction and mitophagy in gemcitabine-resistant pancreatic cancer cells. Co-author DOI 10.1038/s41419-025-07476-5↗
  11. Efficacy of Neoadjuvant Radiotherapy After Chemotherapy and the Optimal Interval from Radiotherapy to Surgery for Borderline Resectable and Resectable Pancreat… Co-author DOI 10.1245/s10434-024-16743-2↗
  12. Changing Clinical Meaning of Resection Margin Status According to the Treatment Paradigm and the Potential Role of Perioperative Radiotherapy for Patients with… Co-author DOI 10.1245/s10434-025-17389-4↗
  13. Evaluating Tumor Regression and Survival Outcomes in Pancreatic Ductal Adenocarcinoma After Neoadjuvant Treatment according to CAP Grading System: Clinical Use… Co-author DOI 10.1245/s10434-025-18123-w↗
  14. Impact of Nutritional Changes on the Prognosis in Pancreatic Cancer Patients Underwent Curative Surgery After Neoadjuvant Chemotherapy. Co-author DOI 10.3390/nu17040647↗
  15. Evaluation of feasibility and clinical outcomes of robot-assisted pancreaticoduodenectomy after neoadjuvant treatment for patients with advanced pancreatic duc… First author DOI 10.4174/astr.2025.109.2.61↗
  16. Re-evaluation of risk and oncological outcomes of resection of veins and arteries in the resection of pancreatic cancer. Co-author DOI 10.1002/jhbp.12048↗
  17. Optimal timing of surgery after neoadjuvant treatment in borderline resectable pancreatic cancer. Co-author DOI 10.1002/jhbp.12049↗
  18. Emerging role of local treatment in the era of advanced systemic treatment in pancreatic cancer with liver metastasis: A systematic review and meta-analysis. Co-author DOI 10.1002/jhbp.12051↗
  19. Efficacy of local treatment for isolated liver metastasis after pancreatectomy in pancreatic ductal adenocarcinoma: A propensity score-matched analysis. Co-author DOI 10.1002/jhbp.1352↗
  20. Prospective Comparison of [18F]FDG and [18F]AIF-FAPI-74 PET/CT in the Evaluation of Potentially Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1007/s11307-024-01950-w↗
  21. Inadequacy of the eighth edition of the American Joint Committee on Cancer pancreatic cancer staging system for invasive carcinoma associated with premalignant… Co-author DOI 10.1016/j.hpb.2023.11.015↗
  22. Development of a Fit-For-Purpose Multi-Marker Panel for Early Diagnosis of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.mcpro.2024.100824↗
  23. Examining neoadjuvant treatment candidates in resectable pancreatic cancer based on tumor-vessel interactions and CA 19-9 levels: a retrospective cohort study. Co-author DOI 10.1097/js9.0000000000001184↗
  24. Clinical outcomes of preservation versus resection of portal/superior mesenteric vein during pancreaticoduodenectomy in pancreatic cancer patients who respond … First author DOI 10.1097/js9.0000000000002034↗
  25. Comparing clinical and genomic features based on the tumor location in patients with resected pancreatic cancer. Co-author DOI 10.1186/s12885-024-12795-5↗
  26. In Neoadjuvant FOLFIRINOX Chemotherapy for Pancreatic Ductal Adenocarcinoma, Which Response is the More Reliable Indicator for Prognosis, Radiologic or Biochem… Co-author DOI 10.1245/s10434-023-14532-x↗
  27. Novel Predictive Strategy Using CA19-9 and Fecal Elastase Levels to Make Treatment Decisions for Resectable Pancreatic Cancer: A Retrospective Study. Co-author DOI 10.3390/biomedicines13010062↗
  28. The role of local treatment including pancreatectomy for pancreatic ductal adenocarcinoma patients with isolated synchronous liver metastasis: Propensity score… Co-author DOI 10.1002/jhbp.1313↗
  29. Reconsidering the absence of extrapancreatic extension in T staging for pancreatic adenocarcinoma in the AJCC (8th ed) Staging Manual using the National Cancer… Co-author DOI 10.1007/s11605-023-05850-2↗
  30. Oncologic Benefits of Neoadjuvant Treatment versus Upfront Surgery in Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis. Co-author DOI 10.3390/cancers14184360↗

Closest collaborators

The 25 strongest of 44 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Wooil Kwon · 30 shared papers, 2022–2026 · strength 6.89
  2. Jin‐Young Jang · 26 shared papers, 2022–2026 · strength 6.03
  3. Won‐Gun Yun · 26 shared papers, 2022–2026 · strength 5.93
  4. Yoon Soo Chae · 13 shared papers, 2024–2026 · strength 3.20
  5. Joon Seong Park · 12 shared papers, 2024–2026 · strength 2.99
  6. Mirang Lee · 12 shared papers, 2022–2025 · strength 2.55
  7. Go‐Won Choi · 9 shared papers, 2025–2026 · strength 2.33
  8. Younsoo Seo · 7 shared papers, 2025–2026 · strength 1.82
  9. Young‐Jae Cho · 4 shared papers, 2024–2025 · strength 0.85
  10. Youngmin Han · 3 shared papers, 2025–2026 · strength 0.76
  11. Seulah Park · 3 shared papers, 2024–2025 · strength 0.69
  12. Jin‐Young Jang · 3 shared papers, 2024–2025 · strength 0.66
  13. Michael D. Kluger · 3 shared papers, 2023–2024 · strength 0.58
  14. Alexander S. Thomas · 3 shared papers, 2023–2024 · strength 0.58
  15. Hyeon Woong Kang · 2 shared papers, 2025 · strength 0.48
  16. Woosol Chris Hong · 2 shared papers, 2025 · strength 0.48
  17. Minsoo Kim · 2 shared papers, 2025 · strength 0.48
  18. Eui Kyu Chie · 2 shared papers, 2024–2025 · strength 0.45
  19. Yoo‐Seok Yoon · 2 shared papers, 2025–2026 · strength 0.44
  20. Chang-Sup Lim · 2 shared papers, 2025–2026 · strength 0.44
  21. Do‐Youn Oh · 2 shared papers, 2024–2026 · strength 0.40
  22. Wonjun Jang · 1 shared paper, 2026 · strength 0.28
  23. Ha Eun Kim · 1 shared paper, 2025 · strength 0.26
  24. Dong Ho Lee · 1 shared paper, 2024 · strength 0.23
  25. Hyung Sun Kim · 1 shared paper, 2024 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.